Cargando…
Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists
[Image: see text] The PD-1/PD-L1 axis has proven to be a highly efficacious target for cancer immune checkpoint therapy with several approved antibodies. Also, small molecules based on a biphenyl core can antagonize PD-1/PD-L1, leading to the in vitro formation of PD-L1 dimers. However, their develo...
Autores principales: | Butera, Roberto, Ważyńska, Marta, Magiera-Mularz, Katarzyna, Plewka, Jacek, Musielak, Bogdan, Surmiak, Ewa, Sala, Dominik, Kitel, Radoslaw, de Bruyn, Marco, Nijman, Hans W., Elsinga, Philip H., Holak, Tad A., Dömling, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155249/ https://www.ncbi.nlm.nih.gov/pubmed/34055224 http://dx.doi.org/10.1021/acsmedchemlett.1c00033 |
Ejemplares similares
-
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Surmiak, Ewa, et al.
Publicado: (2021) -
Design, Synthesis,
and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile
as PD-L1 Antagonist and Its Comparison to Available Small Molecular
PD-L1 Inhibitors
por: Ważyńska, Marta A., et al.
Publicado: (2023) -
Exploring the
Surface of the Ectodomain of the PD-L1
Immune Checkpoint with Small-Molecule Fragments
por: Kitel, Radoslaw, et al.
Publicado: (2022) -
Terphenyl-Based
Small-Molecule Inhibitors of Programmed
Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021) -
CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
por: Musielak, Bogdan, et al.
Publicado: (2019)